Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2015 - 2026)

Rocket Pharmaceuticals (RCKT) has 12 years of Cash from Investing Activities data on file, last reported at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 130.06% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $179.2 million (up 363.93% YoY), and the FY2025 full-year result was $103.8 million, down 21.21% from the prior year.
• Cash from Investing Activities retreated to $17.4 million in Q1 2026, from $36.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $93.6 million in Q3 2025 to a low of -$140.8 million in Q4 2023.
• A 5-year average of $5.0 million and a median of $31.2 million in 2023 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 229.01% in 2022, while the deepest fall reached 743.89% in 2022.
• Tracing RCKT's Cash from Investing Activities over 5 years: stood at -$108.6 million in 2022, then decreased by 29.67% to -$140.8 million in 2023, then surged by 73.1% to -$37.9 million in 2024, then surged by 196.18% to $36.4 million in 2025, then plunged by 52.1% to $17.4 million in 2026.
• Business Quant data shows RCKT's Cash from Investing Activities at $17.4 million in Q1 2026, $36.4 million in Q4 2025, and $93.6 million in Q3 2025.